Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients

Background: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrho...

Full description

Bibliographic Details
Main Authors: Magda Ibrahim, Fathiya El-Raey, Naglaa Fathy, Kadrey El-Bakrey
Format: Article
Language:English
Published: Egyptian knowledge bank 2020-04-01
Series:International Journal of Medical Arts
Subjects:
Online Access:https://ijma.journals.ekb.eg/article_82380_37df342f1483d981733ec70d834c8af1.pdf
id doaj-709c6afa507b4ed8be2a6b9fd04fca2e
record_format Article
spelling doaj-709c6afa507b4ed8be2a6b9fd04fca2e2021-01-15T16:33:21ZengEgyptian knowledge bankInternational Journal of Medical Arts2636-41742682-37802020-04-012241241910.21608/ijma.2020.23373.109482380Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic PatientsMagda Ibrahim0Fathiya El-Raey1Naglaa Fathy2Kadrey El-Bakrey3Department of Physiology (Zoology), Faculty of Science, Damietta University, EgyptDepartment of Hepatogastroenterology and Infectious Diseases, Damietta Faculty of Medicine, Al-Azhar University, EgyptDepartment of Zoology (Physiology), Faculty of Scicene, Damietta University, EgyptDepartment of Zoology (physiology) Faculty of science, Damietta University, EgyptBackground: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrhosis or hepatocellular carcinoma.  Aim of the work: This study aimed to evaluate the potentiality of serum transthyretin [TTR] as a novel biomarker for detection of HCC in cirrhotic patients. Patients and Methods:This Current study was conducted on 70 patients with chronic liver disease. Also, 20 healthy person matched for age and sex were included as a control group. Patients were classified into 2 groups [30 cirrhotic patients with newly diagnosed HCC & 40 cirrhotic patients without HCC]. Serum TTR levels were measured using enzyme linked immunosorbent assay technique. Results: Serum levels of TTR were significantly much lower in HCC patients when compared to cirrhotic patients without HCC or control group [p<0.0001]. Significant decrease of serum TTR in HCC patients, with portal vein invasion or nodal invasion than in HCC without vascular or nodal invasion. The diagnostic accuracy of TTR was higher than that of AFP regarding sensitivity [83.3%] and negative predictive value [81.4%] in diagnosis of HCC. Conclusion: detection of lower level of TTR alone or in combination with other validated markers may be potentially informative biomarker for detection of HCC among cirrhotic patients at early noninvasive stage where curative treatment can be applied.https://ijma.journals.ekb.eg/article_82380_37df342f1483d981733ec70d834c8af1.pdfttransthyretincirrhosishepatocellular carcinomaalpha-fetoproteinnoninvasive
collection DOAJ
language English
format Article
sources DOAJ
author Magda Ibrahim
Fathiya El-Raey
Naglaa Fathy
Kadrey El-Bakrey
spellingShingle Magda Ibrahim
Fathiya El-Raey
Naglaa Fathy
Kadrey El-Bakrey
Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
International Journal of Medical Arts
ttransthyretin
cirrhosis
hepatocellular carcinoma
alpha-fetoprotein
noninvasive
author_facet Magda Ibrahim
Fathiya El-Raey
Naglaa Fathy
Kadrey El-Bakrey
author_sort Magda Ibrahim
title Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_short Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_full Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_fullStr Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_full_unstemmed Transthyretin as a Novel Biomarker for Diagnosis of Hepatocellular Carcinoma in Cirrhotic Patients
title_sort transthyretin as a novel biomarker for diagnosis of hepatocellular carcinoma in cirrhotic patients
publisher Egyptian knowledge bank
series International Journal of Medical Arts
issn 2636-4174
2682-3780
publishDate 2020-04-01
description Background: Hepatocellular carcinoma [HCC] is one of the leading causes of cancer-related deaths worldwide. A major problem with HCC surveillance is the lack of reliable biomarkers. Serum transthyretin [TTR] may be a sensitive marker for the diagnosis of patients with liver cell damage, liver cirrhosis or hepatocellular carcinoma.  Aim of the work: This study aimed to evaluate the potentiality of serum transthyretin [TTR] as a novel biomarker for detection of HCC in cirrhotic patients. Patients and Methods:This Current study was conducted on 70 patients with chronic liver disease. Also, 20 healthy person matched for age and sex were included as a control group. Patients were classified into 2 groups [30 cirrhotic patients with newly diagnosed HCC & 40 cirrhotic patients without HCC]. Serum TTR levels were measured using enzyme linked immunosorbent assay technique. Results: Serum levels of TTR were significantly much lower in HCC patients when compared to cirrhotic patients without HCC or control group [p<0.0001]. Significant decrease of serum TTR in HCC patients, with portal vein invasion or nodal invasion than in HCC without vascular or nodal invasion. The diagnostic accuracy of TTR was higher than that of AFP regarding sensitivity [83.3%] and negative predictive value [81.4%] in diagnosis of HCC. Conclusion: detection of lower level of TTR alone or in combination with other validated markers may be potentially informative biomarker for detection of HCC among cirrhotic patients at early noninvasive stage where curative treatment can be applied.
topic ttransthyretin
cirrhosis
hepatocellular carcinoma
alpha-fetoprotein
noninvasive
url https://ijma.journals.ekb.eg/article_82380_37df342f1483d981733ec70d834c8af1.pdf
work_keys_str_mv AT magdaibrahim transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients
AT fathiyaelraey transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients
AT naglaafathy transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients
AT kadreyelbakrey transthyretinasanovelbiomarkerfordiagnosisofhepatocellularcarcinomaincirrhoticpatients
_version_ 1724336606380294144